CC-BY-NC 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made Highlights Key immune checkpoint receptor-ligand interactions are conserved in marsupials. Live cell-based assays show Tasmanian devil CD28 and CTLA4 can capture CD80 and CD86 in trans from adjacent cells. Mutation of the conserved CTLA4MYPPPY ligand binding motif to CTLA4MYPPPA reduces binding to CD80 and intercellular protein transfer. Removal of conserved CTLA4YVKM protein recycling binding motif in CTLA4 results in bidirectional intercellular protein transfer between CTLA4 and CD80. Highly successful human immune checkpoint immunotherapies have the potential to be translated for veterinary and conservation medicine.
Highlights 33 Key immune checkpoint receptor-ligand interactions are conserved in marsupials. 34 Live cell-based assays show Tasmanian devil CD28 and CTLA4 can capture CD80 35 and CD86 in trans from adjacent cells. 36 Mutation of the conserved CTLA4MYPPPY ligand binding motif to CTLA4MYPPPA 37 reduces binding to CD80 and intercellular protein transfer. 38 Removal of conserved CTLA4YVKM protein recycling binding motif in CTLA4 results 39 in bidirectional intercellular protein transfer between CTLA4 and CD80. 40 Highly successful human immune checkpoint immunotherapies have the potential to 41 be translated for veterinary and conservation medicine. 42 43 Abstract 44 Immune checkpoint immunotherapy is a pillar of human oncology treatment with potential for 45 non-human species. The first checkpoint immunotherapy approved for human cancers targeted 46 the CTLA4 protein. CTLA4 can inhibit T cell activation by capturing and internalizing CD80 47 and CD86 from antigen presenting cells, a process called trans-endocytosis. Similarly, CD28 48 can capture CD80 and CD86 via trogocytosis and retain the captured ligands on the surface of 49 the CD28-expressing cells. The wild Tasmanian devil (Sarcophilus harrisii) population has 50 declined by 77% due to transmissible cancers that evade immune defenses despite genetic 51 mismatches between the host and tumours. We used a live cell-based assay to demonstrate that 52 devil CTLA4 and CD28 can capture CD80 and CD86. Mutation of evolutionarily conserved 53 motifs in CTLA4 altered functional interactions with CD80 and CD86 in accordance with 54 patterns observed in other species. These results suggest that checkpoint immunotherapies can 55 be translated to evolutionarily divergent species. 56 57 Keywords 58 immune checkpoint, wild immunology, transmissible cancer, trans-endocytosis, trogocytosis, 59 intercellular protein transfer 60 Abbreviations 61 intercellular protein transfer (IPT), devil facial tumour (DFT), interferon gamma (IFNγ), major 62 histocompatibility complex (MHC), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4), 63 blue fluorescent protein (BFP) 64 65 We Amanda Patchett, Camila Espejo, Chrissie Ong, Rob Gasperini, and Ruth Pye for 353 assistance in the laboratory and general advice on this project. 354 355
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.